8-K: Theravance Biopharma and Mylan Settle YUPELRI Patent Litigation with Eugia, Securing Market Exclusivity Until 2039

Theravance Biopharma, Inc. and Mylan have reached a settlement agreement with Eugia Pharma Specialities Ltd., resolving patent litigation related to YUPELRI (revefenacin) inhalation solution and delaying Eugia's generic market entry until April 23, 2039.

Summary

• Theravance Biopharma, Inc. (and its subsidiaries) and Mylan (and Viatris Specialty LLC) entered into a Settlement Agreement with Eugia Pharma Specialities Ltd. (and its affiliates) on June 5, 2025.
• The agreement resolves ongoing patent litigation under the Hatch-Waxman Act concerning Eugia's abbreviated new drug application (ANDA) seeking approval for a generic version of YUPELRI (revefenacin) inhalation solution.
• Under the settlement, Theravance and Mylan granted Eugia a royalty-free, non-exclusive, non-sublicensable, non-transferable license to manufacture and market its generic YUPELRI in the United States.
• Eugia is permitted to launch its generic version on or after the Licensed Launch Date of April 23, 2039, subject to customary exceptions.
• The settlement is subject to review by the U.S. Department of Justice and the Federal Trade Commission, as required by law.
• Patent litigation remains pending against two other ANDA filers: Cipla Limited and Mankind Pharma Ltd., along with their affiliates.

Sentiment

Score: 8

Explanation: The settlement resolves a significant patent dispute for a key product, securing market exclusivity from one generic competitor for a substantial period (until 2039). This reduces legal risk and provides long-term revenue visibility for YUPELRI, despite the royalty-free nature of the license. The remaining litigation with other filers is a known ongoing risk.

Positives

• Resolution of one significant patent litigation, reducing legal costs and uncertainty for Theravance and Mylan.
• Secures market exclusivity for YUPELRI (revefenacin) inhalation solution from Eugia's generic competition until at least April 23, 2039, providing a long period of protection.
• The agreement is royalty-free for Eugia, simplifying the terms of the license.

Negatives

• The license granted to Eugia is royalty-free, meaning Theravance will not receive direct revenue from Eugia's future sales of the generic product under this specific agreement.

Risks

• The settlement is subject to review by the U.S. Department of Justice and the Federal Trade Commission, which could potentially challenge or modify the agreement.
• Patent litigation remains pending against two other ANDA filers, Cipla Limited and Mankind Pharma Ltd., indicating continued legal expenses and potential future generic competition from these parties.

Future Outlook

The settlement with Eugia secures market exclusivity for YUPELRI from this specific generic competitor until at least April 23, 2039. However, the company continues to face patent litigation from two other ANDA filers, Cipla Limited and Mankind Pharma Ltd., which will require ongoing legal attention.

Industry Context

This settlement is a common strategy in the pharmaceutical industry under the Hatch-Waxman Act, where brand-name drug manufacturers settle with generic companies to delay the entry of generic versions into the market. Such agreements often involve a 'pay-for-delay' or, as in this case, a 'launch date' agreement, which can extend the period of market exclusivity for the innovator drug, balancing the interests of both parties and potentially avoiding prolonged, costly litigation.

Comparison to Industry Standards

• The settlement's Licensed Launch Date of April 23, 2039, provides a significant period of market exclusivity for YUPELRI against Eugia's generic, which is a favorable outcome compared to earlier generic entry often seen in other patent disputes.
• While the agreement is royalty-free, the primary benefit is the extended market protection, which is a common trade-off in such settlements to avoid the uncertainty and expense of trial.
• Similar agreements have been reached by companies like AbbVie (Humira) and Amgen (Enbrel) to manage generic entry, often involving staggered launch dates for multiple generic competitors.

Legal Proceedings

• Resolution of patent litigation against Eugia Pharma Specialities Ltd., Eugia US LLC, Aurobindo Pharma Limited, and Aurobindo Pharma USA, Inc. regarding YUPELRI (revefenacin) inhalation solution.
• Ongoing patent litigation against Cipla Limited and Mankind Pharma Ltd., along with certain affiliates, related to their ANDA filings for generic YUPELRI.

Stakeholder Impact

• Shareholders: Benefit from reduced legal uncertainty and extended market exclusivity for YUPELRI from one competitor, potentially leading to more stable and predictable revenue streams from the product.
• Customers (patients/healthcare providers): Continued availability of branded YUPELRI without immediate generic competition from Eugia, ensuring product consistency.

Next Steps

• The settlement agreement will undergo review by the U.S. Department of Justice and the Federal Trade Commission.
• Theravance and Mylan will continue to pursue patent litigation against the remaining two ANDA filers, Cipla Limited and Mankind Pharma Ltd.

Key Dates

Recommendation

Keywords

Theravance Biopharma, YUPELRI, revefenacin, patent litigation, settlement agreement, ANDA, generic drug, Hatch-Waxman Act, pharmaceutical, respiratory, market exclusivity, Mylan, Eugia